Imugene (ASX:IMU) has announced that the first patient has been dosed in the combination cohort of the IMPRINTER trial.
The trial is evaluating the safety and efficacy of Imugene’s PD1Vaxx, a B-cell activating immunotherapy alone or in combination with Roche's TECENTRIQ (atezolizumab), which is an immune checkpoint inhibitor targeting PD-L1, in patients with non-small cell lung cancer (NSCLC).
The study will be conducted at sites in the US and Australia.
The company said the combination of PD1-Vaxx may overcome treatment resistance to immune checkpoint inhibitors with dual inhibition of the PD-1/PD-L1 axis extending the treatment benefit of atezolizumab.
“It’s an outstanding accomplishment to see Imugene collaborate with Roche, in combination with our PD1-Vaxx drug," said Leslie Chong, the managing director and CEO of Imugene.
"PD1-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with NSCLC, and with the first patient being dosed today, we are looking forward to evaluating PD1-Vaxx with atezolizumab in ICI treatmentnaïve and pre-treated NSCLC patients.”